Argos Therapeutics
Durham
About Argos Therapeutics
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $238.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2019)
- Ticker: otcqb:ARGS
- Website: argostherapeutics.com
- Phone: (919) 287-6300
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/argos-therapeutics-127698 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.